The interaction of human thrombospondin (TSP) with GPIa-IIa and GPIIb-IIIa was studied. The binding for both proteins became time-independent after 60min. A 7-fold excess concentration of unlabelled GPIa-IIa added either initially, or after 
INTRODUCTION
Thrombospondin (TSP) is a major platelet-secreted protein, that was first purified in its non-denatured state by Lawler and coworkers in 1978 [1] . Since then a great number of studies have been published describing its structure, biological function and tissue distribution. For example, TSP has been found to be a multi-domain protein much like fibronectin with binding sites for heparin [2] , collagen [3] , and fibrinogen [4] . A number of studies have demonstrated that TSP promotes cell-substratum adhesion of a variety of cells including fibroblasts [5] , endothelial cells [5, 6] , epithelial cells [5] and various tumour cell lines such as melanoma cells [5] [6] [7] [8] , small-cell carcinoma cells [8] , and osteosarcoma cells [9] . Recent studies have also postulated a role for TSP in cell proliferation [10] and angiogenesis [11] .
A major interest of ours has been to define a role for TSP in haemostasis. Toward this end, we have observed that TSP promotes platelet aggregation [12] and platelet adhesion [13] . A possible mechanism which might account for our previous observations would require secreted TSP to bind to platelet receptors and cross-link platelets to themselves and to exposed collagen fibrils in the damaged vessel. A similar mechanism, which proposes that TSP stabilizes platelet aggregates by crosslinking platelet-bound fibrinogen, has been proposed previously to explain the role of TSP in platelet aggregation [14] .
Our previous studies have identified two potential platelet TSP-binding proteins which could function to bind secreted TSP.
The first is GPIIb-III., the platelet fibrinogen receptor, which reversibly binds TSP in vitro [15] and antibodies against which inhibit TSP-promoted platelet aggregation and adhesion [13, 15] .
The second is GPIa-IIa, a platelet collagen receptor [16] . It was shown that human platelets from a patient with a bleeding disorder, showing a deficiency of glycoprotein Ia failed to respond to collagen [17] and displayed a decreased platelet adhesion to subendothelium [18] . We GPIa- hIa to TSP was inhibited with anti-(GPIa-IIa) (6F1), whereas mouse IgG and anti-(GPIIb-IIIa) (AP-2) had no effect. (h) The interaction of GPIa-IIa with TSP is 5.5-fold more favourable than that of GPIIb-IIIa suggesting that GPIa-IIa may be a preferred binding protein for TSP-mediated platelet adhesion.
(GPIa-IIa) monoclonal antibodies (mAbs) completely inhibited the TSP-dependent adhesion of normal and thrombasthenic platelets [13] . This inhibition was dose-dependent and complete inhibition could be achieved with as little as 2 ,ug/ml of antibody, while no more than 50 % inhibition of adhesion could be achieved with anti-(GPIIb-IIIa) mAb at concentrations in excess of 50 ,ug/ ml. These results suggested that the interaction of GPI.-II, with TSP must be more favourable than the interaction of GPIIb-IIIa with TSP, despite the fact that platelets contain approx. 50000
Immulon 4, were purchased from Dynatech. CNBr-activated Sepharose was purchased from Pharmacia.
TSP purification TSP was purified from Ca2l ionophore (A23 187)-activated human platelets as described previously [4] .
Protein assays
Protein concentrations were determined by the bicinchoninic acid (BCA) protein assay, adapted for microtitre plates, as described by Pierce. BSA was used as the standard. PAGE SDS/PAGE was performed using the Pharmacia Phast Gel system. Gels were stained, dried on to paper, and autoradiograms were prepared from the dried gels using intensifying screens (DuPont Cronex Lighting Plus screens mounted in Spectroline Cassettes, Reliance X-Ray, Oreland, PA, U.S.A.). Kodak XOmat-AR film was used and developed according to the instructions provided with the film. Films were exposed overnight at -70°C.
Protein labelling Purified GPIIb-IIIa, GPIa-IIa and TSP were labelled with 1251 using lodobeads as described previously [15] . Briefly, 50 ug of purified protein dissolved in octylglucoside buffer (see method for purification of GPI.-IIa and GPIIb-IIIJ) was incubated with one lodobead for 5 min. Unreacted iodide was removed on a small column of Sephadex G-25 equilibrated in octylglucoside buffer as previously described [22] . The specific radioactivities of protein obtained from typical labelling experiments ranged between 5 x 106 and 1 x 107 c.p.m./,ug. When comparing the binding of GPIIb-IIIa with GPIa-IIa specific radio-activities were adjusted to the same value (1 x 105 c.p.m./,ug).
PurMcation of GPI,4-I, and GPIb-lII, GPIa-IIa and GPIIb-IIIa were purified by immunoaffinity chromatography from platelet detergent extracts. Briefly, 5 units of washed platelet pellets, obtained after the centrifugation step following ionophore stimulation to obtain TSP [4] , were dissolved in 10 ml of octylglucoside buffer (50 mM Tris/HCl, pH 7.35, containing 150 mM NaCl, 100 mM octylglucoside, 100 1sM leupeptin and 1 mM phenylmethanesulphonyl fluoride). Undissolved material was removed by centrifugation ofthe detergent extract at 4°C for 30 min at 10000 g. Platelet detergent extract (10 ml) was first passed through an anti (GPIIb-III) mAbSepharose column (prepared by coupling 2 mg of CD41a to 1 ml of CNBr-activated Sepharose according to the instructions provided by Pharmacia) and then over an anti-(GPI.-II8) mAb-Sepharose column (prepared by coupling 2 mg of Gi9 to 1 ml of CNBr-activated Sepharose). Antibody-treated columns were washed with 10 ml of binding buffer, containing 0.5 M NaCl, and eluted withI 00 mM glycine, pH 2.7, containing 50 mM octylglucoside. Fractions (0.5 ml) were collected into tubes containing 10 ,ul of 1 M Tris/HCl added to the collection tubes to neutralize the solution. Peak protein fractions were pooled and concentrated. Wells were saturated with 1 ,ug of adsorbed protein under the conditions of our protein-coating procedure, as determined from radioactive protein studies and the BCA protein assay (results not shown). The amount of radioactive protein bound ranged from 5 to 10 % of input radioactivity. Radioactive protein bound to control BSA-coated wells was, in all experiments, less than 5 % of that bound to TSP or glycoproteins, and was subtracted from experimental values given for test proteins unless otherwise stated. For SDS/polyacrylamide gel analysis, bound GPIa-II& was eluted from immobilized TSP by incubation of washed wells with 50 ,1 of SDS/PAGE sample buffer.
RESULTS

Analysis of purmfied GPI,-II, and GPlib-iliI
The platelet integrins, GPIa-IIa and GPIIb-IIIa, were purified from washed human platelets by antibody-affinity chromatography. The purified integrins were radiolabelled with
[1251I]iodine and typically specific radioactivities of 106 c.p.m./,ug were obtained. The silver-stained as well as the radiolabelled proteins, were characterized on SDS/polyacrylamide gels ( Figure  1 ). The low-molecular-mass impurities in GPIa-IIa are probably proteolytic breakdown products, because they immunoprecipitate with anti-(GPIa-IIa) antibody (results not shown). However, they do not interfere with the binding experiments as GPI.-IIa, which eluted from the binding plates, contained very little of the lower-molecular-mass material (compare lanes 2 and 3 in Figure 1 ). The major polypeptides bound are the undegraded a and f8 chains of GPIa-IIa. The estimated apparent molecular masses obtained for the purified proteins on our gel system (130 and 97 kDa for GPIIb-IIIa and 150 and 120 kDa for GPI.-II.)
were consistent with published values [19, 20] . In addition, SDS/polyacrylamide gel analysis of the 6F1 and AP-2 immunoprecipitates of labelled GPIa-IIa and GPIIb-III. revealed the same bands as shown in Figure 1 (results not shown).
The requirements for binding of GPI,-II, and GPII,-III, to Immobilized TSP, collagen and flbrinogen
The binding of GPI.-IIa to TSP became time-independent after 60 min and could be partially reversed with the addition of a 7-fold excess of unlabelled GPI&-IIa at time zero or after binding had proceeded for 45 min (Figure 2 (Table 2 ). In contrast, GPIIb-IIIa bound fibrinogen in an iondependent manner.
The effect of antl-(GPI,-IlI) antibody on the binding of GPI.-Ii, to TSP To establish further the specificity of the interaction of GPIa-IIa with TSP, we assessed the capacity of anti-(GPI.-II.) (6F1) to block binding. mAb 6F1 has previously been shown by us to quantitatively block TSP-dependent platelet adhesion [13] . We found that 6F1 blocked the binding of GPI. also lend support to our previous studies showing that GPIa-IIa may function as a platelet TSP-binding protein [13] .
To establish that binding of GPIa-IIa to solid-phase TSP is the same as binding to fluid-phase TSP, fluid-phase TSP was evaluated for its capacity to inhibit binding of GPIa-IIa to solidphase TSP. We found that increasing concentrations of fluidphase TSP competed for the binding of solid-phase TSP, whereas IgG and BSA had no effect (Table 3) . Therefore, fluid-phase and solid-phase TSP bind GPIa-IIa.
Comparison of the binding constants for the Interactlon of GPI,-II, and GPIlb-ill, wlth TSP We previously observed that TSP-mediated platelet adhesion could be completely inhibited with anti-(GPIa-IIa) mAbs but only partially inhibited with anti-(GPIIb-IIIJ) mAbs [13] . These results suggested that the interaction of GPIa-IIa with TSP was more favourable than the interaction of GPIIb-IIIa with TSP. To test this hypothesis, the apparent dissociation constant (Kd) for the interaction of TSP with GPIIb-III. was measured and
DISCUSSION
The identity of the cell receptor mediating TSP-dependent celladhesive interactions has been of great interest to us because of our previous work showing that antibodies raised against the platelet fibrinogen receptor, GPIIb-IIIa, inhibited TSP-dependent platelet aggregation [12] and TSP-dependent melanoma cell adhesion [23] , and that GPIIb-IIIa could bind TSP in vitro [15] . Similar observations were made by Lawler and co-workers who showed that (GPIIb-III,)-like integrin receptors could be isolated by TSP-affinity chromatography from endothelial and smooth muscle cells [24] and from platelets [25] . However, the specific functional consequence of these binding interactions remained unclear since GPIIb-III1 and (GPIIb-III)-like integrin receptors display a broad reactivity with a number of adhesive proteins, notably fibrinogen [26] . In addition, several studies have failed to show an interaction of GPIIb-IIIa with TSP in vitro. For example, Leung and Nachman [27] , using an enzyme-linked immunoassay, could demonstrate an interaction between GPIIb-IIIa and fibrinogen but not between GPIIb-IIIa and TSP. Similarly, Pytela et al. [28] , using GPIIb-III. incorporated into liposomes, could not demonstrate an interaction with TSP.
Non-integrin TSP-cell binding proteins have also been described. Human lung small-cell carcinoma has been shown to bind TSP through a two-chain receptor having molecular masses of 80000 and 105000 [29] . Human lung carcinoma cells contain a 50000 molecular-mass CSVTCG-specific TSP receptor [30] . Platelet GPIV or CD36 has been referred to as the platelet TSP receptor because platelet GPIV was found to bind TSP in vitro [31] and GPIV was found to mediate platelet-monocyte interactions in a TSP-dependent manner [32] . However, the presence or absence of CD36 in malaria-parasitized erythrocytes had no effect on TSP binding, suggesting that CD36 is not a TSP receptor in this system [33] . Platelets deficient in GPIV bound TSP to the same extent as normal platelets containing GPIV, suggesting that GPIV is not a TSP receptor in this system as well [34] .
In an effect to identify and characterize platelet TSP receptors further, we recently developed a rapid and sensitive cell-adhesion assay [35] . We have used this assay to identify possible platelet and cell-adhesion receptors. In a recent study aimed at identifying potential platelet TSP receptors, we discovered that antibodies against the platelet fibrinogen receptor, GPIIb-IIIa, and GPIa-IIa, the collagen receptor, inhibited TSP-mediated platelet adhesion [13] .
To establish further that GPIa-IIa and GPIIb-IIII could function as platelet-adhesion receptors, as suggested from our earlier antibody studies, we undertook the present study comparing the binding interactions of GPIa-IIa and GPIIb-IIIa with TSP using an in vitro binding assay. Our results indicate that both GPIa-IIa and GPIIb-IIIa interact with TSP in a reversible and saturable manner. The binding interaction between TSP and GPIa-IIa differs significantly from that of GPIIb-IIIa. GPIa-IIa interacts with TSP in an ion-independent manner, whereas GPIIb-IIIa requires Ca2+ and Mg2+. Although Mn2+ has been shown to promote fibronectin-receptor-mediated adhesion and binding [36] Finally, the binding interaction between GPIa-IIa and TSP is 5.5-fold more favourable than the binding interaction between GPIIbilia and TSP, suggesting that GPIa-IIa may function as a highaffinity platelet TSP-binding protein.
The number of GPIa-IIa sites on platelets has been reported to be 800 per platelet [20] . This number is consistent with the number of TSP molecules binding to non-stimulated platelets which was reported by Wolff et al. [38] to be 760 per platelet in the absence of added bivalent cations. In addition, consistent with the bivalent-cation-independent binding observed in our studies in vitro, these authors observed little or no cation dependence for binding of TSP to unstimulated platelets, finding that in the presence of EDTA, prostaglandin EM (PGE1) and theophylline, 760 molecules per platelet were bound. Our previous studies showing inhibition of TSP-dependent platelet adhesion by anti-(GPIa-IIa) were done using PGE1-treated platelets [13] .
Our results may help to explain the haemorrhagic diathesis of a patient who suffered a bleeding tendency, characterized by frequent petechial bleeding, post-operative haemorrhages and severe menstrual bleeding episodes, necessitating blood transfusions [39] . The patient had a long bleeding time, abnormal collagen-induced adhesion and defective collagen-induced aggregation, but normal ADP-induced aggregation. Analysis of her platelets revealed the absence of GPIa-IIa and the presence of degraded TSP. Intact, exogenously added TSP corrected the platelet-aggregation defect and when TSP and GPIa-IIa appeared in her platelets after menopause, her bleeding tendency disappeared. One explanation for these patient data, as supported by the results of this study, is that TSP can bind either GPIIb-III.
or GPIa-IIa and promote collagen-induced aggregation and adhesion by providing a platelet collagen binding site, as TSP interacts strongly with collagen.
